Dias da Silva VJ, Viana PC, Alves RM, Fazan Jr R, Reis
LC, Porta A, Montano N, and Salgado HC. Effect of amiodarone on the heart rate variability in normotensive and sponta- 18.
neously hypertensive rats (Abstract). FASEB J 14: A56, 2000.
8. Du XJ, Esler MD, and Dart AM. Sympatholytic action of
intravenous amiodarone in the rat heart. Circulation 91: 462–
19.
470, 1995.
9. Echt DS, Leibson PR, Mitchell B, Peters RW, Obias-Manno
20.
D, Barker AH, Arensberg D, Baker A, Friedman W, Green
L, Huther ML, Richardson DW, and the CAST Investigators. Mortality and morbidity in patients receiving encainide,
21.
flecainide or placebo: The Cardiac Arrhythmias Suppression
Trial. N Engl J Med 324: 781–788, 1991.
10. Gloor HO, Urthaler F, and James TN. Acute effects of amiodarone upon the canine sinus node and atrioventricular junc- 22.
tional region. J Clin Invest 71: 1457–1466, 1983.
11. Gough WB, Zeiler RH, Barreca P, and El-Sherif N. Hypotensive action of commercial intravenous amiodarone and poly- 23.
sorbate 80 in dogs. J Cardiovasc Pharmacol 4: 375–380, 1981.
13. Kodama I, Kamiya K, and Toyama J. Amiodarone: ionic and
cellular mechanisms of action of the most promising class III
agent. Am J Cardiol 84: 20R–28R, 1999. 24.
14. Kowey PR, Marinchak RA, Rials SJ, and Filart RA. Intravenous amiodarone. J Am Coll Cardiol 29: 1190–1198, 1997.
15. Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO,
25.
Doherty AM, Fahrenbruch CE, Hallstrom AP, Murray WA,
Olsufka M, and Walsh T. Amiodarone for resuscitation after
out-of-hospital cardiac arrest due to ventricular fibrillation.
26.
N Engl J Med 341: 871–878, 1999.
16. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, and
Schwartz PJ. Baroreflex sensitivity and heart-rate variability
in prediction of total cardiac mortality after myocardial infarction. Lancet 351: 478–484, 1998. 27.
Lombardi F, Colombo A, Basilico B, Ravaglia R, Garbin M,
Vergani D, Battezzati PM, and Fiorentini C. Heart rate
